{
    "brief_title": "Tepotinib in Solid Tumors Harboring MET Alterations",
    "phase": "Phase 2",
    "drugs": "['Tepotinib']",
    "drugs_list": [
        "Tepotinib"
    ],
    "diseases": "['Solid Tumor', 'MET Exon 14 Skipping Mutation', 'MET Amplification']",
    "diseases_list": [
        "Solid Tumor",
        "MET Exon 14 Skipping Mutation",
        "MET Amplification"
    ],
    "enrollment": "100.0",
    "inclusion_criteria": "inclusion criteria: \n\n Histologically or cytologically confirmed solid cancers (NSCLC, gastric cancer, colorectal cancer, breast cancer, hepatocellular cancer, head and neck cancer, RCC and other solid cancers) \n\n Subjects who are not eligible for surgical and/or local-regional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies \n\n Subjects who have disease progression or are intolerant to the prior standard treatment for advanced solid cancers \n\n A tumor biopsy (excluding fine needle aspiration and cytology samples) is required for determining MET status (a fresh pretreatment tumor biopsy is recommended but archived tumor sample is acceptable). \n\n Patients with MET exon 14 skipping mutation detected by NGS method and c-MET copy number gain (\u22656.0) in the archival or fresh tumor tissue specimen identified in K-MASTER panel. All genetic findings must be reviewed by the study Molecular Steering Committee, prior to study entry. \n\n Male or female, 19 years of age or older \n\n Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). The target lesion that has received previous local therapy should not be considered as measurable unless clear progression has been documented since the therapy. \n\n Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 \n\n Signed and dated informed consent indicating that the subject has been informed of all the pertinent aspects of the trial prior to enrollment \n\n Life expectancy judged by the Investigator of at least 3 months \n\n ",
    "exclusion_criteria": ": \n\n 1. Eligibility criteria: \n\n Histologically or cytologically confirmed solid cancers (NSCLC, gastric cancer, colorectal cancer, breast cancer, hepatocellular cancer, head and neck cancer, RCC and other solid cancers) \n\n Subjects who are not eligible for surgical and/or local-regional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies \n\n Subjects who have disease progression or are intolerant to the prior standard treatment for advanced solid cancers \n\n A tumor biopsy (excluding fine needle aspiration and cytology samples) is required for determining MET status (a fresh pretreatment tumor biopsy is recommended but archived tumor sample is acceptable). \n\n Patients with MET exon 14 skipping mutation detected by NGS method and c-MET copy number gain (\u22656.0) in the archival or fresh tumor tissue specimen identified in K-MASTER panel. All genetic findings must be reviewed by the study Molecular Steering Committee, prior to study entry. \n\n Male or female, 19 years of age or older \n\n Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). The target lesion that has received previous local therapy should not be considered as measurable unless clear progression has been documented since the therapy. \n\n Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 \n\n Signed and dated informed consent indicating that the subject has been informed of all the pertinent aspects of the trial prior to enrollment \n\n Life expectancy judged by the Investigator of at least 3 months \n\n 2. ",
    "brief_summary": "The aim of this study is to understand efficacy of tepotinib in patients with solid cancers harbouring c-MET amplification or exon 14 mutation who progressed after standard treatment for metastatic disease.",
    "NCT_ID": "NCT04647838"
}